Efficacy of Stromal Vascular Fraction and Platelet-Rich Plasma Therapy on Post-COVID-19 Nephrotic Syndrome in Diabetic Type 1 Patient: A Case Report
Keywords:coronavirus disease 2019, nephrotic syndrome, platelet-rich plasma, stromal vascular fraction
Extrapulmonary complications in currently infected or recovered COVID-19 patients is a concerning problem. One of these complications is post-COVID nephrotic syndrome which usually requires anti-inflammatory agent for treatment. Among the various anti-inflammatory agents available, the combination of autologous activated platelet-rich plasma (aaPRP) and stromal vascular fraction (SVF) is a potential breakthrough therapy. It not only exerts an anti-inflammatory effect, but also a regenerative effect. To our knowledge, this is the first report of aaPRP and SVF therapy in post-COVID nephrotic syndrome patient. A 27-year-old type 1 diabetic female patient was admitted to Hayandra Clinic with symptoms of nephrotic syndrome after being recovered from COVID-19. The use of SVF and aaPRP combination therapy showed immediate significant improvement in patient’s overall kidney function and clinical manifestations.